Inhibition of interleukin-1 receptor-associated kinase 1 (IRAK1) as a therapeutic strategy

Jack W. Singer, Angela Fleischman, Suliman Al-Fayoumi, John O. Mascarenhas, Qiang Yu, Anupriya Agarwal

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Interleukin-1 receptor-associated kinases (IRAK1, IRAK2, IRAK3 [IRAK-M], and IRAK4) are serine-threonine kinases involved in toll-like receptor and interleukin-1 signaling pathways, through which they regulate innate immunity and inflammation. Evidence exists that IRAKs play key roles in the pathophysiologies of cancers, and metabolic and inflammatory diseases, and that IRAK inhibition has potential therapeutic benefits. Molecules capable of selectively interfering with IRAK function and expression have been reported, paving the way for the clinical evaluation of IRAK inhibition. Herein, we focus on IRAK1, review its structure and physiological roles, and summarize emerging data for IRAK1 inhibitors in preclinical and clinical studies.

Original languageEnglish (US)
Pages (from-to)33416-33439
Number of pages24
JournalOncotarget
Volume9
Issue number70
DOIs
StatePublished - Sep 1 2018

Fingerprint

Interleukin-1 Receptor-Associated Kinases
Toll-Like Receptor 1
Protein-Serine-Threonine Kinases
Metabolic Diseases
Therapeutics
Interleukin-1
Innate Immunity
Inflammation
Neoplasms

Keywords

  • Cancer
  • Inflammatory diseases
  • Interleukin-1 receptor associated kinase (IRAK1)
  • MyD88
  • Pacritinib

ASJC Scopus subject areas

  • Oncology

Cite this

Singer, J. W., Fleischman, A., Al-Fayoumi, S., Mascarenhas, J. O., Yu, Q., & Agarwal, A. (2018). Inhibition of interleukin-1 receptor-associated kinase 1 (IRAK1) as a therapeutic strategy. Oncotarget, 9(70), 33416-33439. https://doi.org/10.18632/oncotarget.26058

Inhibition of interleukin-1 receptor-associated kinase 1 (IRAK1) as a therapeutic strategy. / Singer, Jack W.; Fleischman, Angela; Al-Fayoumi, Suliman; Mascarenhas, John O.; Yu, Qiang; Agarwal, Anupriya.

In: Oncotarget, Vol. 9, No. 70, 01.09.2018, p. 33416-33439.

Research output: Contribution to journalReview article

Singer, JW, Fleischman, A, Al-Fayoumi, S, Mascarenhas, JO, Yu, Q & Agarwal, A 2018, 'Inhibition of interleukin-1 receptor-associated kinase 1 (IRAK1) as a therapeutic strategy', Oncotarget, vol. 9, no. 70, pp. 33416-33439. https://doi.org/10.18632/oncotarget.26058
Singer, Jack W. ; Fleischman, Angela ; Al-Fayoumi, Suliman ; Mascarenhas, John O. ; Yu, Qiang ; Agarwal, Anupriya. / Inhibition of interleukin-1 receptor-associated kinase 1 (IRAK1) as a therapeutic strategy. In: Oncotarget. 2018 ; Vol. 9, No. 70. pp. 33416-33439.
@article{19a6766313d54dbd847cbe1dd986ab74,
title = "Inhibition of interleukin-1 receptor-associated kinase 1 (IRAK1) as a therapeutic strategy",
abstract = "Interleukin-1 receptor-associated kinases (IRAK1, IRAK2, IRAK3 [IRAK-M], and IRAK4) are serine-threonine kinases involved in toll-like receptor and interleukin-1 signaling pathways, through which they regulate innate immunity and inflammation. Evidence exists that IRAKs play key roles in the pathophysiologies of cancers, and metabolic and inflammatory diseases, and that IRAK inhibition has potential therapeutic benefits. Molecules capable of selectively interfering with IRAK function and expression have been reported, paving the way for the clinical evaluation of IRAK inhibition. Herein, we focus on IRAK1, review its structure and physiological roles, and summarize emerging data for IRAK1 inhibitors in preclinical and clinical studies.",
keywords = "Cancer, Inflammatory diseases, Interleukin-1 receptor associated kinase (IRAK1), MyD88, Pacritinib",
author = "Singer, {Jack W.} and Angela Fleischman and Suliman Al-Fayoumi and Mascarenhas, {John O.} and Qiang Yu and Anupriya Agarwal",
year = "2018",
month = "9",
day = "1",
doi = "10.18632/oncotarget.26058",
language = "English (US)",
volume = "9",
pages = "33416--33439",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "70",

}

TY - JOUR

T1 - Inhibition of interleukin-1 receptor-associated kinase 1 (IRAK1) as a therapeutic strategy

AU - Singer, Jack W.

AU - Fleischman, Angela

AU - Al-Fayoumi, Suliman

AU - Mascarenhas, John O.

AU - Yu, Qiang

AU - Agarwal, Anupriya

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Interleukin-1 receptor-associated kinases (IRAK1, IRAK2, IRAK3 [IRAK-M], and IRAK4) are serine-threonine kinases involved in toll-like receptor and interleukin-1 signaling pathways, through which they regulate innate immunity and inflammation. Evidence exists that IRAKs play key roles in the pathophysiologies of cancers, and metabolic and inflammatory diseases, and that IRAK inhibition has potential therapeutic benefits. Molecules capable of selectively interfering with IRAK function and expression have been reported, paving the way for the clinical evaluation of IRAK inhibition. Herein, we focus on IRAK1, review its structure and physiological roles, and summarize emerging data for IRAK1 inhibitors in preclinical and clinical studies.

AB - Interleukin-1 receptor-associated kinases (IRAK1, IRAK2, IRAK3 [IRAK-M], and IRAK4) are serine-threonine kinases involved in toll-like receptor and interleukin-1 signaling pathways, through which they regulate innate immunity and inflammation. Evidence exists that IRAKs play key roles in the pathophysiologies of cancers, and metabolic and inflammatory diseases, and that IRAK inhibition has potential therapeutic benefits. Molecules capable of selectively interfering with IRAK function and expression have been reported, paving the way for the clinical evaluation of IRAK inhibition. Herein, we focus on IRAK1, review its structure and physiological roles, and summarize emerging data for IRAK1 inhibitors in preclinical and clinical studies.

KW - Cancer

KW - Inflammatory diseases

KW - Interleukin-1 receptor associated kinase (IRAK1)

KW - MyD88

KW - Pacritinib

UR - http://www.scopus.com/inward/record.url?scp=85053068246&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053068246&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.26058

DO - 10.18632/oncotarget.26058

M3 - Review article

VL - 9

SP - 33416

EP - 33439

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 70

ER -